MX358785B - Hemoglobina pegilada reticulada con diaspirina. - Google Patents
Hemoglobina pegilada reticulada con diaspirina.Info
- Publication number
- MX358785B MX358785B MX2014011763A MX2014011763A MX358785B MX 358785 B MX358785 B MX 358785B MX 2014011763 A MX2014011763 A MX 2014011763A MX 2014011763 A MX2014011763 A MX 2014011763A MX 358785 B MX358785 B MX 358785B
- Authority
- MX
- Mexico
- Prior art keywords
- diaspirin
- pegylated hemoglobin
- crosslinked pegylated
- diaspirin crosslinked
- hemoglobin
- Prior art date
Links
- PREOBXYMXLETCA-UHFFFAOYSA-N 2-[4-(2-carboxyphenoxy)-4-oxobutanoyl]oxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC(=O)CCC(=O)OC1=CC=CC=C1C(O)=O PREOBXYMXLETCA-UHFFFAOYSA-N 0.000 title 1
- 102000001554 Hemoglobins Human genes 0.000 title 1
- 108010054147 Hemoglobins Proteins 0.000 title 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 abstract 1
- 108010025915 Nitrite Reductases Proteins 0.000 abstract 1
- 229910002091 carbon monoxide Inorganic materials 0.000 abstract 1
- 108010074807 diaspirin-cross-linked hemoglobin Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
- C04B35/634—Polymers
- C04B35/63448—Polymers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- C04B35/63488—Polyethers, e.g. alkylphenol polyglycolether, polyethylene glycol [PEG], polyethylene oxide [PEO]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261617639P | 2012-03-29 | 2012-03-29 | |
| PCT/US2013/032694 WO2013148375A1 (en) | 2012-03-29 | 2013-03-15 | Diaspirin crosslinked pegylated hemoglobin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014011763A MX2014011763A (es) | 2015-08-07 |
| MX358785B true MX358785B (es) | 2018-09-04 |
Family
ID=49261107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014011763A MX358785B (es) | 2012-03-29 | 2013-03-15 | Hemoglobina pegilada reticulada con diaspirina. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10029001B2 (enExample) |
| EP (1) | EP2830638B1 (enExample) |
| JP (2) | JP2015514086A (enExample) |
| KR (1) | KR102144139B1 (enExample) |
| CN (2) | CN109731098A (enExample) |
| AU (1) | AU2013240141B2 (enExample) |
| CA (1) | CA2908236C (enExample) |
| HK (1) | HK1207560A1 (enExample) |
| MX (1) | MX358785B (enExample) |
| WO (1) | WO2013148375A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201912805SA (en) * | 2014-12-19 | 2020-02-27 | Aragon Pharmaceuticals Inc | Process for the preparation of a diarylthiohydantoin compound |
| CN105017515A (zh) * | 2015-07-20 | 2015-11-04 | 湖南华腾制药有限公司 | 聚乙二醇修饰物的制备方法 |
| CN106421805B (zh) * | 2016-09-14 | 2019-06-04 | 中国人民解放军军事医学科学院野战输血研究所 | 一种右旋糖酐交联血红蛋白氧载体及其制备方法与应用 |
| CA3070172A1 (en) | 2017-07-18 | 2019-01-24 | VirTech Bio, Inc. | Blood substitutes comprising hemoglobin and methods of making |
| WO2022184005A1 (en) | 2021-03-01 | 2022-09-09 | Billion King International Limited | Thiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof |
| CN114146165B (zh) * | 2021-12-02 | 2022-08-12 | 润方（北京）生物医药研究院有限公司 | 一种聚合血红蛋白在制备防治呼吸衰竭药物中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4529719A (en) | 1983-05-04 | 1985-07-16 | Tye Ross W | Modified crosslinked stroma-free tetrameric hemoglobin |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| CA1312009C (en) | 1986-11-10 | 1992-12-29 | Carl W. Rausch | Extra pure semi-synthetic blood substitute |
| US5234903A (en) | 1989-11-22 | 1993-08-10 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute |
| US5585484A (en) | 1995-04-19 | 1996-12-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Hemoglobin crosslinkers |
| US6627738B2 (en) | 1995-09-15 | 2003-09-30 | Duke University | No-modified hemoglobins and uses therefor |
| AU2002320628A1 (en) | 2001-07-19 | 2003-03-03 | Albert Einstein College Of Medecine Of Yeshiva University | Size enhanced hemoglobins: surface decoration and crosslinking of the protein with polyoxy akylene glycols |
| US20050164915A1 (en) * | 2002-04-01 | 2005-07-28 | Sangart, Inc. | Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| US20030153491A1 (en) | 2002-01-11 | 2003-08-14 | Winslow Robert M. | Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| US7144989B2 (en) | 2002-03-25 | 2006-12-05 | Albert Einstein College Of Medicine Of Yeshiva University | Pegylated non-hypertensive hemoglobins, methods of preparing same, and uses thereof |
| CA2511494A1 (en) | 2002-12-23 | 2004-07-15 | Seetharama A. Acharya | Non-hypertensive polyethylene glycol-modified hemoglobin as oxygen carrier |
| KR100512483B1 (ko) | 2003-05-07 | 2005-09-05 | 선바이오(주) | 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법 |
| AU2005279780B2 (en) * | 2004-08-31 | 2011-02-03 | Sangart, Inc. | Methods to enhance hemodynamic stability using oxygen carrying compositions |
| WO2006096774A2 (en) * | 2005-03-07 | 2006-09-14 | Sangart, Inc. | Composition and methods for delivering carbon monoxide (co) and nitric ozide (no) co to tissue using heme proteins as carriers |
| US8741832B2 (en) | 2005-06-10 | 2014-06-03 | Albert Einstein College Of Medicine Of Yeshiva University | Pegylated albumin and uses thereof |
| US7504377B2 (en) * | 2006-10-23 | 2009-03-17 | Ikor, Inc. | Nitric oxide-blocked cross-linked tetrameric hemoglobin |
| CN102859364A (zh) * | 2010-02-25 | 2013-01-02 | 桑格特公司 | 通过减少反应物比例制备聚乙二醇-血红蛋白缀合物的方法 |
| US20130052232A1 (en) | 2011-08-31 | 2013-02-28 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking |
-
2013
- 2013-03-15 US US14/388,956 patent/US10029001B2/en active Active
- 2013-03-15 JP JP2015503348A patent/JP2015514086A/ja active Pending
- 2013-03-15 CN CN201910069033.4A patent/CN109731098A/zh active Pending
- 2013-03-15 CA CA2908236A patent/CA2908236C/en active Active
- 2013-03-15 EP EP13769757.9A patent/EP2830638B1/en active Active
- 2013-03-15 CN CN201380027621.2A patent/CN104379160A/zh active Pending
- 2013-03-15 HK HK15108131.6A patent/HK1207560A1/xx unknown
- 2013-03-15 MX MX2014011763A patent/MX358785B/es active IP Right Grant
- 2013-03-15 AU AU2013240141A patent/AU2013240141B2/en not_active Ceased
- 2013-03-15 WO PCT/US2013/032694 patent/WO2013148375A1/en not_active Ceased
- 2013-03-15 KR KR1020147030304A patent/KR102144139B1/ko not_active Expired - Fee Related
-
2019
- 2019-01-17 JP JP2019005963A patent/JP6668515B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN109731098A (zh) | 2019-05-10 |
| CN104379160A (zh) | 2015-02-25 |
| EP2830638B1 (en) | 2021-05-05 |
| WO2013148375A1 (en) | 2013-10-03 |
| JP2015514086A (ja) | 2015-05-18 |
| US10029001B2 (en) | 2018-07-24 |
| AU2013240141A1 (en) | 2014-11-13 |
| KR102144139B1 (ko) | 2020-08-12 |
| EP2830638A4 (en) | 2015-12-16 |
| JP2019089789A (ja) | 2019-06-13 |
| AU2013240141B2 (en) | 2017-11-02 |
| KR20150009533A (ko) | 2015-01-26 |
| CA2908236C (en) | 2021-10-26 |
| EP2830638A1 (en) | 2015-02-04 |
| HK1207560A1 (en) | 2016-02-05 |
| JP6668515B2 (ja) | 2020-03-18 |
| MX2014011763A (es) | 2015-08-07 |
| US20150087590A1 (en) | 2015-03-26 |
| CA2908236A1 (en) | 2013-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX358785B (es) | Hemoglobina pegilada reticulada con diaspirina. | |
| EP4303236A3 (en) | Cytotoxicity-inducing therapeutic agent | |
| PH12013500899A1 (en) | Modified factor ix polypeptides and uses thereof | |
| EA201101522A1 (ru) | Способы лечения болезней с использованием эпиметаболического переключателя (коэнзим q10) | |
| NZ630805A (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| TN2012000611A1 (en) | Formulations of rifaximin and uses thereof | |
| NZ700073A (en) | Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane | |
| MX353315B (es) | Compuestos de imidazopirrolidinona. | |
| PH12014501639B1 (en) | Pharmaceutical compositions and methods | |
| TW201129377A (en) | Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho | |
| GB201020860D0 (en) | Disulfiram formulation and uses thereof | |
| WO2007146425A3 (en) | Compounds and methods for treatment of chemotherapy-induced anemia | |
| WO2014089209A3 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins | |
| WO2010093705A3 (en) | Synthetic rna-based agonists of tlr7 | |
| AU2011274619A8 (en) | miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway | |
| WO2013061083A3 (en) | Therapeutic agents and uses thereof | |
| TN2012000457A1 (en) | Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | |
| WO2009105585A3 (en) | Postsynaptically targeted chemodenervation agents and their methods of use | |
| WO2009095261A3 (en) | Vaccine compositions | |
| MX2012013875A (es) | Anticuerpos de union sparc en sangre periferica y usos de los mismos. | |
| MX342313B (es) | Peptidos a base de lactoferrina humana que tienen actividad antiinflamatoria. | |
| MX2014010940A (es) | El uso de antitrombina en el tratamiento de preeclampsia. | |
| WO2012090207A3 (en) | Par1 and par2 c-tail peptides and peptide mimetics | |
| EP4361634A3 (en) | Methods for treating and monitoring the status of cancer | |
| MX344189B (es) | Formulaciones de mazindol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |